Long Beach Memorial Medical Center

Summary

Long Beach Memorial Medical Center is a medical facility located in Long Beach, California. This center is recognized for care of Stroke, Breast Cancer, Cancer, Coronary Artery Disease, Leukemia and other specialties. Long Beach Memorial Medical Center is involved with conducting 140 clinical trials across 271 conditions. There are 18 research doctors associated with this hospital, such as Nirav Patel, Ali Khoynezhad, MD, Jasmin Dao, and Jimmy Johannes, MD.

Top PIs

Clinical Trials running at Long Beach Memorial Medical Center

Respiratory Distress Syndrome

Migraine

Cancer

Acute Lung Injury

Acute Respiratory Distress Syndrome

Stroke

Cystic Fibrosis

Respiratory Impairment

Chronic Lymphocytic Leukemia

Vestibular Migraine

Various Treatments

for Critically Ill COVID-19 Patients

The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

Recruiting

2 awards

Phase 2

4 criteria

Innovative Therapies

for Acute Respiratory Distress Syndrome

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments. This record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding intervention-specific records on clinicaltrials.gov listed below in the detailed description.

Recruiting

0 awards

Phase 2

1 criteria

Vilobelimab

for Acute Respiratory Distress Syndrome

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort A: Participants will be randomized to receive either a placebo or vilobelimab. This record describes the default procedures and analyses for Cohort A. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.

Recruiting

0 awards

Phase 2

1 criteria